S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
OTCMKTS:ENDV

Endonovo Therapeutics Stock Forecast, Price & News

$0.02
0.00 (-2.70%)
(As of 11/26/2021 12:26 PM ET)
Add
Compare
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.01
$0.10
Volume
30,013 shs
Average Volume
423,191 shs
Market Capitalization
$1.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive ENDV News and Ratings via Email

Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Endonovo Therapeutics logo

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

Headlines

Endonovo Therapeutics Issues Shareholder Update
October 12, 2021 |  finance.yahoo.com
Endonovo Therapeutics Inc (ENDV)
October 20, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ENDV
Employees
1
Year Founded
N/A

Sales & Book Value

Annual Sales
$170 thousand
Cash Flow
$0.02 per share
Book Value
($0.29) per share

Profitability

Net Income
$-400 thousand
Net Margins
-8,913.61%
Pretax Margin
-8,913.61%

Debt

Price-To-Earnings

Miscellaneous

Free Float
60,092,000
Market Cap
$1.15 million
Optionable
Not Optionable

Company Calendar

Today
11/27/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Endonovo Therapeutics (OTCMKTS:ENDV) Frequently Asked Questions

How has Endonovo Therapeutics' stock price been impacted by Coronavirus?

Endonovo Therapeutics' stock was trading at $0.3150 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ENDV shares have decreased by 94.3% and is now trading at $0.0180.
View which stocks have been most impacted by COVID-19
.

Who are Endonovo Therapeutics' key executives?

Endonovo Therapeutics' management team includes the following people:
  • Alan Brian Collier, Chairman, CEO, CFO & Secretary
  • Don Calabria, Vice President-Operations
  • David Clark, Vice President-Sales
  • Steven Ford, Vice President-Marketing
  • Steven Barnes, Investor Relations Contact

What other stocks do shareholders of Endonovo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Ekso Bionics (EKSO), Geron (GERN), Marinus Pharmaceuticals (MRNS), Micron Technology (MU), Novavax (NVAX) and Exxon Mobil (XOM).

What is Endonovo Therapeutics' stock symbol?

Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV."

How do I buy shares of Endonovo Therapeutics?

Shares of ENDV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Endonovo Therapeutics' stock price today?

One share of ENDV stock can currently be purchased for approximately $0.02.

How much money does Endonovo Therapeutics make?

Endonovo Therapeutics has a market capitalization of $1.15 million and generates $170 thousand in revenue each year.

How many employees does Endonovo Therapeutics have?

Endonovo Therapeutics employs 1 workers across the globe.

What is Endonovo Therapeutics' official website?

The official website for Endonovo Therapeutics is www.endonovo.com.

Where are Endonovo Therapeutics' headquarters?

Endonovo Therapeutics is headquartered at 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367.

How can I contact Endonovo Therapeutics?

Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The biotechnology company can be reached via phone at (800) 489-4774, via email at [email protected], or via fax at 818-230-9899.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.